Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05145764 · ClinicalTrials.gov registry record · Phase 2

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

A Phase 2 study of Opioid Use Disorder and Placebo, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
1
Study location

NCT05145764 is a Phase 2 study of Opioid Use Disorder and Placebo that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 120 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05145764, a Phase 2 study of Opioid Use Disorder and Placebo, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine/naloxone and transitioned to extended-release buprenorphine).

Conditions Studied

Opioid Use Disorder Placebo Suvorexant

Interventions

  • DRUG Placebo
  • DRUG Suvorexant

Study Locations (1)

Maryland

  • Johns Hopkins Bayview Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2022-03-30
Est. Completion 2026-08
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05145764

The ClinicalTrials.gov registry entry for NCT05145764 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (97% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05145764 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT05145764 about?

NCT05145764 is a clinical study titled "Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl". This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpa...

What is the current status of trial NCT05145764?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-03-30. Estimated completion is 2026-08.

What conditions does trial NCT05145764 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Placebo, Suvorexant.

What interventions are being tested in trial NCT05145764?

The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).

Who is sponsoring clinical trial NCT05145764?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05145764 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Opioid Use Disorder

All registered trials for this condition

Placebo

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.